Royalty Pharma plc, RPRX, FDA Calendar, PDUFA Date

Company Name	Royalty Pharma plc RPRX
Drug Name	Zidesamtinib (NDA)
Event Name	FDA decision on Zidesamtinib for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer in adults
Event Date	09/18/2026
Outcome Date
Outcome	Pending
Drug Status
Rival Drugs	Bristol Myers Squibb's Repotrectinib (Augtyro), Nuvation Bio Inc's Taletrectinib (Ibtrozi), Roche's Entrectinib (Rozlytrek), and Pfizer's Crizotinib (Xalkori).
Market Potential
Other Approvals
News

Return to FDA Calendar

Slide Shows